EMIS Ethical Principles

Impact of COVID-19 COVID-19 has had a transformative impact on healthcare delivery. It has revolutionised ways of working across the healthcare

Potential Benefits of Collaborative Working

We have seen this in the rapid vaccine rollout to combat COVID-19 – without collaboration and research, we would not be in the promising position we are today. Likewise, in the guidance publication ‘Saving and improving lives: the future of UK clinical research delivery’, the Government has highlighted the vital role of collaboration in our response to COVID-19: “The spirit of collaboration shown by all those involved in this phenomenal research effort has been fundamental to our success. Regulators, the NHS and trial sponsors have worked hand-in- hand to set-up and deliver large-scale trials safely, quickly and effectively.”

For Patients: • New, effective treatments are available more quickly

landscape and thrown a spotlight onto the essential role of clinical trials and research.

• Better and more personalised information about conditions and treatment options

The NHS Long TermPlan is clear that research and innovation is key to drive future outcomes and improvement. It outlines an explicit intent: “We will work to increase the number of people registering to participate in health research to one million by 2023/24.“ This recognises that breakthroughs enable prevention of ill-health, earlier diagnosis, more effective treatments, better outcomes and faster recovery.

• Higher quality care and better health outcomes

For Clinicians:

• Better support to deliver high quality care

• Diagnostic aids, care pathway protocols, alerts & templates supporting implementation of National Standards and NHS Policy

• Involvement in cutting edge research and development

“ Clinical research is the backbone of healthcare – it is the way we improve the detection, diagnosis, treatment, and prevention of disease and improves the lives of patients across the country. This has never been more true than in our response to the pandemic.” - Matt Hancock, Former Secretary of State for Health and Social Care 23rd March 2021

For the Research & Life Science Partner:

• New knowledge, interventions and treatments are accelerated

• Increase in the appropriate use of treatments aligned to national guidance

• Faster implementation of central policy to bring new treatments into the NHS

• Potential increase in size of the relevant and eligible patient population